Publications by authors named "Quinty Vellema"
Cancer Lett
November 2024
Article Synopsis
- High-risk neuroblastoma has a dismal outlook, underscoring the need for innovative treatment strategies, particularly targeting Rho GTPase signaling which has been linked to both the disease and resistance to therapies.
- The dual ROCK inhibitor RKI-1447 showed significant anti-cancer effects by reducing tumor growth, boosting cell death, and inhibiting key oncogenes like N-MYC in both lab and animal studies.
- Combining RKI-1447 with BET inhibitors like ABBV-075 enhanced treatment effects and helped in overcoming resistance, presenting a potential strategy to improve neuroblastoma therapies while minimizing side effects.
